Titan Pharmaceuticals (TTNP) Stock Price, News & Analysis

Company Overview

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

Key Stats

• Today's Range: $4.24 to $4.48
• 50-Day Range: $3.55 to $5.30
• 52-Week Range: $3.03 to $14.80
• Volume: 7,064 shs
• Average Volume: 41,232 shs
• Market Capitalization: $3.97 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TTNP Stock Analysis - Frequently Asked Questions

How have TTNP shares performed this year?

Titan Pharmaceuticals' stock was trading at $3.26 at the beginning of 2025. Since then, TTNP shares have increased by 30.7% and is now trading at $4.26.
View the best growth stocks for 2025 here.

How were Titan Pharmaceuticals' earnings last quarter?

Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) released its quarterly earnings results on Wednesday, May, 14th. The specialty pharmaceutical company reported ($0.62) earnings per share (EPS) for the quarter.

When did Titan Pharmaceuticals' stock split?

Shares of Titan Pharmaceuticals reverse split on the morning of Tuesday, January 9th 2024. The 1-20 reverse split was announced on Tuesday, January 9th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 9th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Titan Pharmaceuticals?

Shares of TTNP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Titan Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Titan Pharmaceuticals investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), CrowdStrike (CRWD) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 6/23/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TTNP
• CIK: 910267
• Web: www.titanpharm.com
• Phone: (650) 244-4990
• Fax: 650-244-4956
• Employees: 10
• Year Founded: 1992

Profitability

• EPS (Most Recent Fiscal Year): ($4.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.71 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -145.92%
• Return on Assets: -129.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.73
• Quick Ratio: 7.73

Sales & Book Value

• Annual Sales: $180 thousand
• Price / Sales: 22.04
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.67 per share
• Price / Book: 1.63

Miscellaneous

• Outstanding Shares: 910,000
• Free Float: 907,000
• Market Cap: $3.97 million
• Optionable: Optionable
• Beta: 1.30